Changes in prostate cancer screening practice by blood PSA testing between 2011 and 2017, a French population-based study

References

• Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin North Am. 2017;101(4):787–806.
   PubMed Web of Science ®Google Scholar
• Carter HB. Prostate-Specific Antigen (PSA) screening for prostate cancer: revisiting the evidence. JAMA. 2018;319(18):1866–1868.
   PubMed Web of Science ®Google Scholar
• Dépistage du cancer de la prostate – Analyse critique des articles issus des études ERSPC et PLCO publiés en mars 2009 [Internet]. Haute Autorité de Santé; [cited 2019 Sep 5]. Available from: https://www.has-sante.fr/jcms/c_961182/fr/depistage-du-cancer-de-la-prostate-analyse-critique-des-articles-issus-des-etudes-erspc-et-plco-publies-en-mars-2009.
   Google Scholar
• National Cancer Institute. Prostate Cancer Screening (PDQ®)–Health Professional Version [Internet]. National Cancer Institute. 2019; [cited 2019 Sep 5]. Available from: https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq.
   Google Scholar
• Ilic D, Neuberger MM, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database of Systematic Reviews [Internet]. 2013; [cited 2019 Sep 5]; Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004720.pub3/full.
   Google Scholar
• Rozet F, Hennequin C, Beauval J-B, et al. Prog Urol. French ccAFU guidelines – Update 2018-2020: Prostate Cancer]. 2018;28(Suppl 1):R81–R132.
   Google Scholar
• Kale MS, Korenstein D. Overdiagnosis in primary care: framing the problem and finding solutions. BMJ. 2018;362:k2820.
   PubMed Web of Science ®Google Scholar
• Welch HG, Albertsen PC. Reconsidering prostate cancer mortality – the future of PSA screening. N Engl J Med. 2020;382(16):1557–1563.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Black A, Parnes HL, et al. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012;36(6):e401–e406.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019;123(5):854–860.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening – a perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285–1289.
   PubMed Web of Science ®Google Scholar
• Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449–455.
   PubMed Web of Science ®Google Scholar
• de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. 2018;124(6):1197–1206.
   PubMed Web of Science ®Google Scholar
• Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
   PubMed Web of Science ®Google Scholar
• American Urological Association. Prostate cancer: early detection guideline 2018. [Internet]; [cited 2019 Sep 5]. Available from: https://www.auanet.org/guidelines/prostate-cancer-early-detection-guideline.
   Google Scholar
• Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297–316.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé. Rapport d’orientation – Cancer de la prostate [Internet]. 2012 ; [cited 2021 Jun 16]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2012-04/rapport_dorientation_-_cancer_de_la_prostate_2012-04-03_16-39-9_898.pdf.
   Google Scholar
• Salomon L, Azria D, Bastide C, et al. Recommendations Onco-Urology 2010: prostate cancer. Prog Urol. 2010;20(Suppl 4):S217–S251.
   PubMedGoogle Scholar
• Salomon L, Bastide C, Beuzeboc P, et al. CCAFU recommendations 2013: prostate cancer. Prog Urol. 2013;23(Suppl 2):S69–S101. [
   PubMed Web of Science ®Google Scholar
• Roquefeuil LD, Studer A, Neumann A, et al. L’échantillon généraliste de bénéficiaires: représentativité, portée et limites. Pratiques et Organisation Des Soins. 2009;40(3):213–223. Vol.
   Google Scholar
• Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d'information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–S167.
   PubMed Web of Science ®Google Scholar
• LOI n° 2016-41 du 26 janvier 2016 de modernisation de notre système de santé. 2016-41 Jan 26, 2016.
   Google Scholar
• Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883–895.
   PubMed Web of Science ®Google Scholar
• Tabayoyong W, Abouassaly R. Prostate cancer screening and the associated controversy. Surg Clin North Am. 2015;95(5):1023–1039.
   PubMed Web of Science ®Google Scholar
• R. Zlotta A, V. Carlsson S, Finelli A, et al. Re: reconsidering prostate cancer mortality – the future of psa screening. European Urology. 2020;78(6):927–929.
   PubMed Web of Science ®Google Scholar
• Borghesi M, Suardi N, Terrone C. Re: reconsidering prostate cancer mortality – the future of PSA screening: the future of PSA screening by reconsidering prostate cancer mortality. Eur Urol. 2020;382(16):1557–1563.
   Google Scholar
• U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191.
   PubMed Web of Science ®Google Scholar
• Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–134.
   PubMed Web of Science ®Google Scholar
• Misra-Hebert AD, Hu B, Klein EA, et al. Prostate cancer screening practices in a large, integrated health system: 2007–2014. BJU Int. 2017;120(2):257–264.
   PubMed Web of Science ®Google Scholar
• Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part ii: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801–2814.
   PubMed Web of Science ®Google Scholar
• Frendl DM, Epstein MM, Fouayzi H, et al. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data. Cancer Causes Control. 2020;31(9):861–867.
   PubMed Web of Science ®Google Scholar
• Presti J, Alexeeff S, Horton B, et al. Changes in prostate cancer presentation following the 2012 USPSTF screening statement: observational study in a multispecialty group practice. J Gen Intern Med. 2020;35(5):1368–1374.
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–1913.
   PubMed Web of Science ®Google Scholar
• Ministère des Affaires sociales et de la Santé, Ministre de l’Enseignement supérieur et de la Recherche. Plan Cancer 2014-2019 [Internet]. 2015; [cited 2019 Sep 5]. Available from: https://www.e-cancer.fr/Plan-cancer/Plan-cancer-2014-2019-priorites-et-objectifs.
   Google Scholar
• Tuppin P, Leboucher C, Samson S, et al. Vers une évolution des pratiques de détection et de prise en charge. Bull Epidemiol Hebd. 2016;9:156–163.
   Google Scholar
• Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761–769.
   PubMed Web of Science ®Google Scholar
• Droz J-P, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404-414–e414.
   Web of Science ®Google Scholar
• Détection précoce du cancer de la prostate - Actualisation du référentiel de pratiques de l’examen périodique de santé (EPS) - Mai 2013. [Internet]; [cited 2019 Sep 5]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2013-07/referentieleps_format2clic_kc_prostate_vfinale.pdf.
   Google Scholar
• Tuppin P, Leboucher C, Peyre-Lanquar G, et al. [Rates of total and free PSA prescriptions in France (2012–2014)]. Presse Med. 2017;46(10):e237–e247.
   PubMed Web of Science ®Google Scholar
• Francois T, Alezra E, Kikassa J-C, et al. [Screening of prostate cancer seen by general practitioners]. Prog Urol. 2013;23(16):1407–1411.
   PubMed Web of Science ®Google Scholar
• Schoenborn NL, Xue Q-L, Pollack CE, et al. Demographic, health, and attitudinal factors predictive of cancer screening decisions in older adults. Prev Med Rep. 2019;13:244–248.
   PubMedGoogle Scholar
• Janssen EM, Pollack CE, Boyd C, et al. How do older adults consider age, life expectancy, quality of life, and physician recommendations when making cancer screening decisions? Results from a national survey using a discrete choice experiment. Med Decis Making. 2019;39(6):621–631.
   PubMed Web of Science ®Google Scholar
• Morère J-F, Touboul C, Lhomel C, et al. [Prostate cancer screening in France: results from the EDIFICE surveys]. Prog Urol. 2020;30(6):332–338.
   PubMed Web of Science ®Google Scholar